 ORPH stock has a virtually impossible task ahead of it in picking itself after FDAs rejection of the Danish biopharmas Arimoclomol drug. The post Orphazyme Stock Is a Dead-End for Investors After FDA Rejection appeared first on InvestorPlace. 